Mizuho Markets Americas LLC Has $7.29 Million Holdings in BridgeBio Pharma, Inc. $BBIO

19 Jan 2026, 07:50 by Amy Steele · The Cerbat Gem

Mizuho Markets Americas LLC boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 46.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,372 shares of the company’s stock after purchasing an additional 44,300 shares during the quarter. Mizuho Markets Americas LLC owned about 0.07% of BridgeBio Pharma worth $7,291,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BBIO. GAMMA Investing LLC boosted its holdings in shares of BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after buying an additional 227 shares during the period. Steward Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after acquiring an additional 228 shares during the last quarter. Gabelli Funds LLC boosted its stake in shares of BridgeBio Pharma by 0.3% during the 2nd quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock worth $3,185,000 after buying an additional 250 shares during the last quarter. Main Management ETF Advisors LLC raised its stake in shares of BridgeBio Pharma by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company’s stock worth $981,000 after purchasing an additional 372 shares in the last quarter. Finally, Wealth Management Associates Inc. lifted its stake in BridgeBio Pharma by 4.7% in the third quarter. Wealth Management Associates Inc. now owns 8,900 shares of the company’s stock valued at $462,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Stock Performance

Shares of BBIO opened at $76.26 on Monday. The business’s 50 day moving average price is $72.97 and its two-hundred day moving average price is $59.13. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $79.88. The firm has a market cap of $14.70 billion, a PE ratio of -18.24 and a beta of 1.17.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The company had revenue of $120.70 million during the quarter, compared to the consensus estimate of $107.71 million. During the same quarter last year, the firm posted ($0.86) earnings per share. The firm’s revenue was up 4318.0% compared to the same quarter last year. Research analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: Lower near-term interest cost and extended maturity — the new notes carry 0.75% interest vs. the company’s 2.50% 2027 notes and push maturity to 2033, which should reduce cash interest expense and extend refinancing risk, improving balance-sheet flexibility. BridgeBio Prices Offering (GlobeNewswire)
Positive Sentiment: Share repurchase tied to the deal reduces near-term float and may support the stock while also pushing the effective conversion price higher (helps limit immediate dilution). Management is using ~$82.5M cash to repurchase ~1.1M shares concurrently with the note pricing. QuiverQuant deal summary
Positive Sentiment: Analyst/Wall Street tone is constructive — brokerages give a consensus “Moderate Buy” and recent price targets (median ≈ $86) remain above current levels, which supports investor confidence. Consensus Recommendation (AmericanBankingNews)
Neutral Sentiment: Conversion terms limit near-term dilution — the initial conversion price is ~45% above the last trade, and conversions are restricted until certain conditions/periods (convertibility becomes more open closer to maturity), so dilution risk is muted in the short run. Finanznachrichten pricing details
Negative Sentiment: Increased leverage and potential future dilution — the company is issuing incremental convertible debt (structurally junior to some obligations) and conversion or future redemptions could dilute equity holders over time; the offering is private (Rule 144A) and not registered. QuiverQuant private offering note
Negative Sentiment: Insider selling and institutional adjustments noted in public data could weigh on sentiment — recent disclosures show sizable insider sales and some large institutional rebalances, which investors may view as a cautionary signal. QuiverQuant insider & institutional data

Insider Buying and Selling

In other news, Director Andrew Lo sold 55,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total value of $3,612,950.00. Following the transaction, the director owned 50,583 shares of the company’s stock, valued at approximately $3,322,797.27. This represents a 52.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronald J. Daniels sold 61,031 shares of BridgeBio Pharma stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $63.72, for a total value of $3,888,895.32. Following the sale, the director directly owned 16,991 shares of the company’s stock, valued at approximately $1,082,666.52. This trade represents a 78.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 587,215 shares of company stock valued at $39,569,101 in the last three months. Insiders own 18.20% of the company’s stock.

Analysts Set New Price Targets

BBIO has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of BridgeBio Pharma in a report on Monday, November 3rd. Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Leerink Partners lifted their price target on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Finally, Sanford C. Bernstein started coverage on BridgeBio Pharma in a research report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price target on the stock. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average price target of $78.85.

Check Out Our Latest Stock Report on BridgeBio Pharma

About BridgeBio Pharma

(Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.